Skip to main content
GRI
NASDAQ Life Sciences

GRI Bio Seeks 546,529-Share Equity Plan Expansion, Lifting Overhang to 21%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$2.07
Mkt Cap
$4.591M
52W Low
$1.36
52W High
$64.12
52W Position info
52% above low
Off High info
97% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

GRI sits 52% above its 52-week low of $1.36 on light trading volume (0.4× avg).

Summary

GRI Bio's definitive proxy seeks approval to expand its equity incentive plan by 546,529 shares, raising potential dilution to 21% of outstanding shares, and to extend the evergreen provision to 2036.


Key Events · Corporate Governance and Compliance · GRI

  • Equity Plan Expansion Proposed

    Proposal 3 seeks to increase shares authorized under the A&R 2018 Plan by 546,529, from 34,951 to 581,480 shares, raising equity overhang from 1.57% to 21.01%.

  • Evergreen Provision Extended to 2036

    The amendment extends the evergreen provision to January 1, 2036, adding annual increases of 4% of outstanding shares each year through 2036.

  • Annual Meeting Scheduled

    The 2026 Annual Meeting will be held virtually on November 4, 2026, with a record date of September 22, 2026 and 2,186,115 shares eligible to vote.

  • Auditor Ratification

    Proposal 2 seeks ratification of WithumSmith+Brown, PC as independent auditor for fiscal 2026, following the April 2025 dismissal of Sadler, Gibb & Associates.


Analysis · GRI · Life Sciences

The proxy asks shareholders to approve a 546,529-share increase to the 2018 Equity Incentive Plan, which would raise the equity overhang from 1.57% to 21.01% of outstanding shares. For a micro-cap company with a going-concern warning and a market value below Nasdaq's proposed $5 million MVLS threshold, this expansion is a material governance and dilution event. The plan also extends the evergreen provision to 2036, allowing automatic annual increases of 4% of outstanding shares. The annual meeting is set for November 4, 2026.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GRI was trading at $2.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6M. The 52-week trading range was $1.36 to $64.12. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GRI - Latest Insights

GRI
Nov 13, 2026, 5:11 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.70
Real-time Price: $1.58 info
Change: -$0.120 (-7%) info
Market Cap: $3.52M info
GRI
Sep 08, 2026, 8:16 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.60
Real-time Price: $1.58 info
Change: -$1.02 (-39%) info
Market Cap: $3.52M info
GRI
Aug 24, 2026, 9:05 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.70
Real-time Price: $1.58 info
Change: -$0.1219 (-7%) info
Market Cap: $3.52M info
GRI
Aug 14, 2026, 7:44 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.88
Real-time Price: $1.58 info
Change: -$0.300 (-16%) info
Market Cap: $3.52M info
GRI
Jun 18, 2026, 4:50 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.90
Real-time Price: $1.58 info
Change: -$0.3195 (-17%) info
Market Cap: $3.52M info